In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates

Phylogenetic Relationships Matter: Antifungal Susceptibility among Clinically Relevant Yeasts

(2013) A. F. Schmalreck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B

(2013) João F. Lacerda et al.   CLINICAL DRUG INVESTIGATION

Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex

(2013) Rolin L. Wade et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Facultative Sterol Uptake in an Ergosterol-Deficient Clinical Isolate of Candida glabrata Harboring a Missense Mutation inERG11and Exhibiting Cross-Resistance to Azoles and Amphotericin B

(2012) Claire M. Hull et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Two Clinical Isolates of Candida glabrata Exhibiting Reduced Sensitivity to Amphotericin B Both Harbor Mutations inERG2

(2012) Claire M. Hull et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

(2012) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

Interlaboratory Reproducibility of Etest Amphotericin B and Caspofungin Yeast Susceptibility Testing and Comparison with the CLSI Method

(2012) S. Ranque et al.   JOURNAL OF CLINICAL MICROBIOLOGY

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update

(2010) J Maertens et al.   BONE MARROW TRANSPLANTATION

Species distribution andin vitroantifungal susceptibility of clinicalCandidaisolates from a university hospital in Turkey over a 5-year period

(2010) Nuri Kiraz et al.   MEDICAL MYCOLOGY

Effect of Antifungal Therapy Timing on Mortality in Cancer Patients with Candidemia

(2009) Y. Taur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Guías de práctica clínica para el manejo de la candidiasis: actualización del 2009, de la Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Liposomal Amphotericin B

(2009) Marit D. Moen et al.   DRUGS

In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods

(2009) D. J. Diekema et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

(2008) C. Lass-Florl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

(2008) J.L. Rodriguez-Tudela et al.   CLINICAL MICROBIOLOGY AND INFECTION

Trends in Species Distribution and Susceptibility of Bloodstream Isolates of Candida Collected in Monterrey, Mexico, to Seven Antifungal Agents: Results of a 3-Year (2004 to 2007) Surveillance Study

(2008) G. M. Gonzalez et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Renal impairment and Amphotericin B formulations in patients with invasive fungal infections

(2008) Faouzi Saliba et al.   MEDICAL MYCOLOGY

Resistance to Antifungal Agents: Mechanisms and Clinical Impact

(2007) Z. A. Kanafani et al.   CLINICAL INFECTIOUS DISEASES